Anticoagulant Pradaxa’s sales jumped 6.8% to 1.4 billion euros, though the drug lags behind its rivals, Bayer/J&J's Xarelto and Pfizer/BMS's Eliquis, in market share terms. Meanwhile diabetes ...
Purpose The pharmacology, pharmacokinetics, efficacy, and safety of apixaban are reviewed. Summary Apixaban is an oral, direct, selective factor Xa inhibitor with a rapid onset of action.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback